| 发布于: | 雪球 | 转发：0 | 回复：0 | 喜欢：0 |
$Karyopharm(KPTI)$ Time to buy KPTI again. Three way to win: ASCO/EHA data, FDA approval run up, FDA early approval. Could see the price go back to 4 if FDA rejects in July but you will have plenty of time to exit your position.